ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting").
美國南舊金山和加拿大溫哥華，2024 年 3 月 7 日 /PRNewswire/-ESSA Pharma Inc. (”ESSA“或者”公司“）（納斯達克股票代碼：EPIX）是一家專注於開發治療前列腺癌的新療法的臨床階段製藥公司，很高興地宣佈其在2024年3月6日虛擬舉行的年度股東大會上審議的事項的投票結果（”會議“)。
At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, Sandy Zweifach, Philip Kantoff and Lauren Merendino to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:
在會議上，公司的股東（”股東“）決定將公司董事人數定爲十人，並通過投票表決通過的普通決議再次當選爲董事會成員，戴維·帕金森、理查德·格里克曼、加里·索利斯、富蘭克林·伯傑、斯科特·雷卡特、瑪雷拉·索雷爾、亞歷克斯·馬丁、桑迪·茨韋法奇、菲利普·坎托夫和勞倫·梅倫迪諾將任職至下次年會或直到他們的繼任者正式成立當選或任命。有關董事選舉的詳細投票結果如下：
|
Nominee |
Votes For |
% Votes For |
Votes Withheld |
% Votes Withheld |
|
David R. Parkinson |
29,947,985 |
99.73 % |
81,989 |
0.27 % |
|
Richard MGlickman |
29,948,035 |
99.73 % |
81,939 |
0.27 % |
|
Gary Sollis |
29,945,788 |
99.72 % |
84,186 |
0.28 % |
|
Franklin M. Berger |
29,937,249 |
99.69 % |
92,725 |
0.31 % |
|
Scott Requadt |
29,947,985 |
99.73 % |
81,989 |
0.27 % |
|
MarellaThorell |
23,840,414 |
79.39 % |
6,189,560 |
20.61 % |
|
Alex Martin |
30,014,431 |
99.95 % |
15,543 |
0.05 % |
|
Sandy Zweifach |
30,013,358 |
99.94 % |
16,616 |
0.06 % |
|
Philip Kantoff |
30,014,381 |
99.95 % |
15,593 |
0.05 % |
|
Lauren Merendino |
30,015,635 |
99.95 % |
14,339 |
0.05 % |
|
提名人 |
投贊成票 |
% 投贊成票 |
被扣留的選票 |
被扣留的選票百分比 |
|
大衛·R·帕金森 |
29,947,985 |
99.73% |
81,989 |
0.27% |
|
理查德·麥格里克曼 |
29,948,035 |
99.73% |
81,939 |
0.27% |
|
加里·索利斯 |
29,945,788 |
99.72% |
84,186 |
0.28% |
|
富蘭克林·伯傑 |
29,937,249 |
99.69% |
92,725 |
0.31% |
|
斯科特·雷卡特 |
29,947,985 |
99.73% |
81,989 |
0.27% |
|
MarellaThorell |
23,840,414 |
79.39% |
6,189,560 |
20.61% |
|
亞歷克斯·馬丁 |
30,014,431 |
99.95% |
15,543 |
0.05% |
|
Sandy Zweifach |
30,013,358 |
99.94% |
16,616 |
0.06% |
|
菲利普·坎托夫 |
30,014,381 |
99.95% |
15,593 |
0.05% |
|
勞倫·梅倫迪諾 |
30,015,635 |
99.95% |
14,339 |
0.05% |
At the Meeting, the Shareholders also approved: (i) the re-appointment of Davidson & Company LLP, Chartered Professional Accountants, as auditors of the Company; (ii) an amendment to the Company's omnibus incentive plan (as amended, the "Amended Omnibus Plan") to increase the number of common shares of the Company reserved and available for issuance under the Amended Omnibus Plan; and (iii) on a non-binding advisory basis, the compensation of the Company's named executive officers.
在會議上，股東們還批准了：（i）重新任命戴維森公司特許專業會計師事務所爲公司核數師；（ii）對公司綜合激勵計劃的修正案（經修訂的，”經修訂的綜合計劃“）增加根據經修訂的綜合計劃預留和可供發行的公司普通股數量；以及（iii）在不具約束力的諮詢基礎上，增加公司指定執行官的薪酬。
Contact Information:
聯繫信息：
David Wood
Chief Financial Officer, ESSA Pharma Inc.
T: 778-331-0962
E: [email protected]
大衛伍德
ESSA 製藥公司首席財務官
電話：778-331-0962
E: [電子郵件保護]
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit and follow us on Twitter under @ESSAPharma.
ESSA是一家臨床階段的製藥公司，專注於開發用於治療前列腺癌患者的新型專有療法。欲了解更多信息，請在 Twitter 上訪問並關注我們 @ESSAPharma。
SOURCE ESSA Pharma Inc
來源 ESSA Pharma
譯文內容由第三人軟體翻譯。